Key result
Hyperlipidemia affects 91% of cardiac transplant patients within 5 years, highlighting the need for second-line agents despite a lack of good quality evidence.
This review highlights the clinical challenges and lack of high-quality evidence for managing hyperlipidemia with second-line agents in cardiac transplant patients.
Emphasizes persistent hyperlipidemia challenges post-transplant; leaves open optimal second-line therapies due to limited evidence.
Despite widespread statin therapy, 91% of cardiac transplant patients have hyperlipidemia within 5 years from cardiac transplantation. The implications of this are profound, particularly given that coronary allograft vasculopathy is a leading cause of death. Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. We review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2012) conducted a review in Hyperlipidemia after cardiac transplantation. Second line agents for hyperlipidemia was evaluated. Hyperlipidemia affects 91% of cardiac transplant patients within 5 years, highlighting the need for second-line agents despite a lack of good quality evidence.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: